Mobile Site ›
Print Friendly View

Test ID: MENMS    
Multiple Endocrine Neoplasia Type 2 (2A, 2B, FMTC) Mutation Screen

Secondary ID A test code used for billing and in test definitions created prior to November 2011

80573

NY State Approved Indicates the status of NY State approval and if the test is orderable for NY State clients.

Conditional

Useful For Suggests clinical disorders or settings where the test may be helpful

Confirmation of diagnosis of multiple endocrine neoplasia type 2 (MEN 2), MEN 2B, and familial medullary thyroid carcinoma (FMTC)

 

Documentation of germline mutation to distinguish FMTC from sporadic multifocal medullary thyroid carcinoma

Genetics Test Information Provides information that may help with selection of the correct test or proper submission of the test request

Includes sequencing of the following exons: 10, 11, 13-16.

Special Instructions and Forms Describes specimen collection and preparation information, test algorithms, and other information pertinent to test. Also includes pertinent information and consent forms to be used when requesting a particular test

Method Name A short description of the method used to perform the test

Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing of Exons 10, 11, 13, 14, 15, and 16 of the RET Proto-onocogene
(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)

Reporting Name A shorter/abbreviated version of the Published Name for a test; an abbreviated test name

MEN2 (2A,2B,FMTC) Mutation Screen

Aliases Lists additional common names for a test, as an aid in searching

Endocrine Cancer Syndrome
Familial Medullary Thyroid Carcinoma
FMTC
MEN2A
MEN2B
Multiple Endocrine Neoplasia Type 2A
Multiple Endocrine Neoplasia Type 2B
RET proto-oncogene (see Q&A for more info)
RET